At Evaluate, we provide news, analysis, data and insight for the professionally curious. We don’t tell you what to think. Instead, we believe it’s more important that you can ask your own questions and have the information to draw your own conclusions. So you can fill in the gaps on pharma - and spot opportunities others miss.
Free pharmaceutical news and analysis to stimulate your thoughts.
The commercial data to build your response.
Matthew C., Director, R&D Strategy and Operations, Gilead
Thanks for your interest in Evaluate
Stimulus | |||
---|---|---|---|
Daily news with expert analysis | |||
Interviews with industry leaders | |||
Company & product events coverage | |||
Response | |||
Consensus forecasts to 2024 | |||
Archived consensus forecasts | |||
Sales by indication | |||
Therapy area, mechanism of action, and other classifications | |||
Licensing deals, M&A, venture financing and IPOs | |||
Orphan drugs and biosimilars analysis | |||
Success rate benchmarks (PTRS) | |||
Time-in-phase benchmarks by indication | |||
Comprehensive product and trial level R&D costs | |||
Clinical trials design and outcomes | |||
Net Present Value calculator | |||
Calendar of market events and catalysts |
We know Evaluate has done the work and looked at the data, and we trust the answers they give us. Our management is happy when they see Evaluate’s names on the data.
- Anthony M, Senior Director Competitive Intelligence & Prospection, Novartis
Evaluate accelerates my work - getting me up to speed quickly on the dynamics and current valuations within a market so I can formulate a successful strategy for my client.
- Partner, Top 10 Consultancy
Evaluate is such an important resource for us. Finding the information we need in ten minutes in Evaluate makes a meaningful difference for our clients, because we can increase the quantity and quality of options we show them.
- Vishwas S, Vice President, Bank of America